All News

Male hormonal contraceptives applied daily to the skin appear to reduce sperm production, according to a new study presented at the Endocrine Society annual meeting in Houston.

American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.

U.S. Senator Barbara Boxer (D-CA) and Congressman Elijah Cummings (D-MD) recently introduced the Prostate Cancer Detection Research and Education Act, legislation that would improve research and detection of prostate cancer.

A recent study has pinpointed four genes linked to prostate cancer, a finding that researchers say could significantly improve diagnosis and treatment by identifying slow-growing cancers that do not need to be treated and by developing targeted therapies for aggressive forms of the disease.

The FDA has approved the once-daily oral beta-3 adrenergic agonist mirabegron (Myrbetriq) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Scientists at Washington University School of Medicine in St. Louis have found new clues to why some urinary tract infections recur persistently after multiple rounds of treatment.

Testosterone replacement therapy may result in weight reduction and improvement in symptoms of metabolic syndrome, according to separate studies presented at the Endocrine Society annual meeting in Houston.

The FDA recently granted pre-market approval to Prostate Health Index (phi), a noninvasive blood test that manufacturer Beckman Coulter, Inc. claims is 2.5 times more specific in detecting prostate cancer than PSA in patients with PSA values in the 4.0 to 10.0 ng/mL range.

The American Institute of Ultrasound in Medicine (AIUM) and the AUA have announced the collaborative development of practice and training guidelines in the practice of urologic ultrasound, which has led to the availability of practice accreditation through the AIUM.

Some 190,000 men in the U.S. with non-metastatic prostate cancer were receiving continuous androgen deprivation therapy (ADT) at the end of 2008.

While on the surface, it may not seem to matter, there are some important differences between debit and credit cards, and reasons why you should use one form of payment over the other.

Whenever an employee leaves, you incur expenses to advertise the open position and set up and train a new employee. And, of course, there can be productivity losses in the interim.

Most urologists say they've already seen reaction to the report's release and the resulting news coverage. Many are concerned that the USPSTF recommendation will give men another excuse to avoid the doctor's office.

In a recent audit of urodynamics charges, Medicare recognized some codes but not others, and the documentation for all services that were reviewed only included the report from the urodynamics machine. This review pointed out the lack of understanding of these codes by payers and physicians.

Analyses of data from the Prostate Cancer Outcomes Study (PCOS) show that among men with localized prostate cancer, treatment by radical prostatectomy results in significantly better 15-year overall and disease-specific survival outcomes compared with external beam radiotherapy (EBRT).

Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.

Combining the results of the diagnostic and first-surveillance prostate biopsies provides useful information about the risk of progression in patients being managed by active surveillance.

Urologists find HIFU promising, but remain cautious

PSA screening is on the rise and varies according to age, family history, race/ethnicity, and insurance status.

Androgen deprivation therapy (ADT) prior to salvage cryoablation appears to improve post-treatment morbidity to some extent but does not affect biochemical-free survival.

Results of a retrospective study provide evidence supporting the use of ultrasound as follow-up imaging to detect relapses in patients with germ cell tumors (GCT).

Here are the take-home messages from the 2012 AUA annual meeting-cutting-edge research findings in 15 areas of clinical urology.

Patients being treated with oral anticancer drugs for metastatic renal cell carcinoma (mRCC) demonstrate almost full adherence to their medication regimen, data show.

With all of the pressure on the federal government to curtail spending, the U.S. Department of Health and Human Services (HHS) is not kidding around when it comes to investigating and prosecuting Medicare fraud and abuse.

Urology drugs and devices in the pipeline from Janssen Research and Development, LLC; Auxilium Pharmaceuticals, Inc.; Tengion Inc.; Ampio Pharmaceuticals, Inc.; Tokai Pharmaceuticals, ImaginAb, Inc.; BZL Biologics, LLC; Agensys, Inc.; and Seattle Genetics, Inc.

Repeat intradetrusor injections of onabotulinumtoxinA (Botox) are associated with sustained efficacy and no new safety signals.

PSA is performing appropriately, allowing us to diagnose prostate cancers at an earlier stage and grade and allowing treatment while cure is still possible.